Literature DB >> 8223871

Cleavage and inactivation of human C1 inhibitor by the human leukocyte proteinase, proteinase 3.

R W Leid1, B E Ballieux, I van der Heijden, C Kleyburg-van der Keur, E C Hagen, L A van Es, F J van der Woude, M R Daha.   

Abstract

Incubation of highly purified human C1 inhibitor with equally pure human leukocyte proteinase 3, resulted in a dose- and time-dependent inactivation of C1 inhibitor hemolytic activity. Furthermore, this inactivation was accompanied by proteinase 3-dependent cleavage of the C1 inhibitor into an 83,000 molecular weight fragment. The formation of the 83,000 molecular weight fragment followed a time course which was similar to that observed for the inactivation of hemolytic activity. Within 120 minutes more than 90% of the hemolytic activity was lost. This inactivation of C1 inhibitor appeared to be selective as purified human C1q was not degraded in a similar time period. Moreover, when 100 micrograms IgG, isolated from each of 21 Wegener's granulomatosis patients with cytoplasmic anti-nuclear antibodies immunofluorescent titers to proteinase 3 greater then 1:64, was incubated with 3 milliunits of proteinase 3, little to no cleavage of C1 inhibitor was observed. In contrast, 100 micrograms of IgG isolated from 14 normal donors was ineffective in affording protection to C1 inhibitor upon incubation with proteinase 3. Our results suggest that neutrophil infiltration and activation could lead to local complement consumption at the tissue sites.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8223871     DOI: 10.1002/eji.1830231132

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  14 in total

1.  Characterization of monoclonal antibodies to proteinase 3 (PR3) as candidate tools for epitope mapping of human anti-PR3 autoantibodies.

Authors:  Y M Van Der Geld; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  Distinctive roles of neutrophils and monocytes in anti-thy-1 nephritis.

Authors:  R Westerhuis; S C van Straaten; M G van Dixhoorn; N van Rooijen; N A Verhagen; C D Dijkstra; E de Heer; M R Daha
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

3.  Anti-C1q receptor/calreticulin autoantibodies in patients with systemic lupus erythematosus (SLE).

Authors:  R H van den Berg; C E Siegert; M C Faber-Krol; T W Huizinga; L A van Es; M R Daha
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

4.  C3 and C4 allotypes in anti-neutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis.

Authors:  U Persson; L Truedsson; K W Westman; M Segelmark
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

5.  Kinetics of thrombomodulin release and endothelial cell injury by neutrophil-derived proteases and oxygen radicals.

Authors:  Michael W J Boehme; Peter Galle; Wolfgang Stremmel
Journal:  Immunology       Date:  2002-11       Impact factor: 7.397

6.  Binding of proteinase 3 and myeloperoxidase to endothelial cells: ANCA-mediated endothelial damage through ADCC?

Authors:  B E Ballieux; K T Zondervan; P Kievit; E C Hagen; L A van Es; F J van der Woude; M R Daha
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

7.  A proportion of proteinase 3 (PR3)-specific anti-neutrophil cytoplasmic antibodies (ANCA) only react with PR3 after cleavage of its N-terminal activation dipeptide.

Authors:  J Sun; D N Fass; M A Viss; A M Hummel; H Tang; H A Homburger; U Specks
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

8.  Recombinant proteinase 3 (Wegener's antigen) expressed in Pichia pastoris is functionally active and is recognized by patient sera.

Authors:  M C Harmsen; P Heeringa; Y M van der Geld; M G Huitema; A Klimp; A Tiran; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

9.  Diversity of PR3-ANCA epitope specificity in Wegener's granulomatosis. Analysis using the biosensor technology.

Authors:  Agnieszka A Rarok; Ymke M van der Geld; Coen A Stegeman; Pieter C Limburg; Cees G M Kallenberg
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.317

10.  Interference of PR3-ANCA with the enzymatic activity of PR3: differences in patients during active disease or remission of Wegener's granulomatosis.

Authors:  Y M van der Geld; A T J Tool; J Videler; M de Haas; J W Cohen Tervaert; C A Stegeman; P C Limburg; C G M Kallenberg; D Roos
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.